Table Graph
   

anti-inflammatoty and immuno-therapy - versus standard of care - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.04 [0.67, 1.61]< 10%4 studies (4/-)43.3 %highnot evaluable lowcrucial-
death or transfer to ICU 1.07 [0.73, 1.57]< 10%1 study (1/-)36.6 %NAnot evaluable crucial-
deaths 1.04 [0.67, 1.60]< 10%6 studies (6/-)43.4 %highnot evaluable lowcrucial-
clinical deterioration 0.78 [0.32, 1.89]< 136%2 studies (2/-)71.1 %highnot evaluable lowimportant-
clinical improvement 0.68 [0.21, 2.20]> 10%1 study (1/-)25.9 %NAnot evaluable important-
clinical improvement (14-day) 2.03 [0.17, 24.32]> 175%2 studies (2/-)71.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.91 [1.03, 3.53]> 10%1 study (1/-)98.0 %NAnot evaluable important-
mechanical ventilation 0.94 [0.52, 1.70]< 10%2 studies (2/-)58.0 %highnot evaluable lowimportant-
radiologic improvement (14-day) 2.87 [1.56, 5.28]> 10%1 study (1/-)100.0 %NAnot evaluable important-
viral clearance 2.69 [1.48, 4.87]> 10%2 studies (2/-)99.9 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.18 [0.00, 435.69]> 198%2 studies (2/-)34.4 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.78 [0.91, 3.47]> 169%3 studies (3/-)95.4 %some concernnot evaluable moderateimportant-
ICU admission 0.47 [0.08, 2.69]< 10%1 study (1/-)80.1 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.40 [0.03, 4.70]< 10%2 studies (2/-)76.4 %some concernnot evaluable moderateimportant-
adverse events 1.71 [0.84, 3.49]< 10%2 studies (2/-)7.1 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons